{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:28:46Z","timestamp":1770150526200,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05733-9","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:02:20Z","timestamp":1713326540000},"page":"3881-3888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines"],"prefix":"10.1007","volume":"103","author":[{"given":"Charalampos","family":"Charalampous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"issue":"8","key":"5733_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107","journal-title":"Am J Hematol"},{"issue":"3","key":"5733_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M et al (2022) Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia 36(3):801\u2013808","journal-title":"Leukemia"},{"issue":"6","key":"5733_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.25764","volume":"95","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Majhail NS (2020) Treatment and disease-related complications in multiple myeloma: implications for survivorship. Am J Hematol 95(6):672\u2013690","journal-title":"Am J Hematol"},{"key":"5733_CR4","doi-asserted-by":"crossref","unstructured":"Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel), 12(1)","DOI":"10.3390\/cancers12010191"},{"issue":"9","key":"5733_CR5","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","volume":"112","author":"SY Kristinsson","year":"2008","unstructured":"Kristinsson SY et al (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112(9):3582\u20133586","journal-title":"Blood"},{"issue":"1","key":"5733_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2022000414","volume":"2022","author":"F Covut","year":"2022","unstructured":"Covut F, Sanfilippo KM (2022) Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy. Hematol Am Soc Hematol Educ Program 2022(1):363\u2013367","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"21","key":"5733_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"11","key":"5733_CR8","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","volume":"107","author":"V De Stefano","year":"2022","unstructured":"De Stefano V et al (2022) Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 107(11):2536\u20132547","journal-title":"Haematologica"},{"issue":"4","key":"5733_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933\u2013939 quiz 1093","journal-title":"Blood"},{"issue":"8","key":"5733_CR10","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29(8):986\u2013993","journal-title":"J Clin Oncol"},{"issue":"2","key":"5733_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423","journal-title":"Leukemia"},{"issue":"23","key":"5733_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood.2022015727","volume":"140","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R et al (2022) Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood 140(23):2443\u20132450","journal-title":"Blood"},{"issue":"3","key":"5733_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajh.26806","volume":"98","author":"C Charalampous","year":"2023","unstructured":"Charalampous C et al (2023) Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival. Am J Hematol 98(3):413\u2013420","journal-title":"Am J Hematol"},{"issue":"9","key":"5733_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","volume":"136","author":"CA Bradbury","year":"2020","unstructured":"Bradbury CA et al (2020) Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood 136(9):1091\u20131104","journal-title":"Blood"},{"issue":"3","key":"5733_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjh.18432","volume":"199","author":"DW Sborov","year":"2022","unstructured":"Sborov DW et al (2022) Daratumumab plus Lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol 199(3):355\u2013365","journal-title":"Br J Haematol"},{"issue":"8","key":"5733_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/cncr.32682","volume":"126","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R et al (2020) Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis. Cancer 126(8):1640\u20131650","journal-title":"Cancer"},{"issue":"8","key":"5733_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/jth.13741","volume":"15","author":"MP Winter","year":"2017","unstructured":"Winter MP, Schernthaner GH, Lang IM (2017) Chronic complications of venous thromboembolism. J Thromb Haemost 15(8):1531\u20131540","journal-title":"J Thromb Haemost"},{"key":"5733_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CEOR.S39964","volume":"5","author":"AA Khorana","year":"2013","unstructured":"Khorana AA et al (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101\u2013108","journal-title":"Clinicoecon Outcomes Res"},{"key":"5733_CR19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"38","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV (2018) Value and cost of Myeloma Therapy. Am Soc Clin Oncol Educ Book 38:662\u2013666","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"5733_CR20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY et al (2012) Thrombosis is associated with inferior survival in multiple myeloma. Haematologica 97(10):1603\u20131607","journal-title":"Haematologica"},{"issue":"7","key":"5733_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/rth2.12411","volume":"4","author":"MW Schoen","year":"2020","unstructured":"Schoen MW et al (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 4(7):1203\u20131210","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"5733_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41408-021-00513-4","volume":"11","author":"R Chakraborty","year":"2021","unstructured":"Chakraborty R et al (2021) Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. Blood Cancer J 11(6):121","journal-title":"Blood Cancer J"},{"issue":"5","key":"5733_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/MBC.0000000000000296","volume":"26","author":"H Huang","year":"2015","unstructured":"Huang H, Li H, Li D (2015) Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis 26(5):555\u2013559","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"5733_CR24","first-page":"844","volume":"110","author":"X Leleu","year":"2013","unstructured":"Leleu X et al (2013) MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost 110(4):844\u2013851","journal-title":"Thromb Haemost"},{"issue":"10","key":"5733_CR25","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"10294","key":"5733_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","volume":"398","author":"F Khan","year":"2021","unstructured":"Khan F et al (2021) Venous thromboembolism. Lancet 398(10294):64\u201377","journal-title":"Lancet"},{"issue":"1","key":"5733_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/CH-131691","volume":"55","author":"HC Kwaan","year":"2013","unstructured":"Kwaan HC (2013) Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc 55(1):75\u201383","journal-title":"Clin Hemorheol Microcirc"},{"issue":"6","key":"5733_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","volume":"129","author":"A Cortelezzi","year":"2005","unstructured":"Cortelezzi A et al (2005) Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 129(6):811\u2013817","journal-title":"Br J Haematol"},{"issue":"2","key":"5733_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cncr.26302","volume":"118","author":"EJ Anaissie","year":"2012","unstructured":"Anaissie EJ et al (2012) Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 118(2):549\u2013557","journal-title":"Cancer"},{"issue":"5","key":"5733_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","volume":"126","author":"M Zangari","year":"2004","unstructured":"Zangari M et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126(5):715\u2013721","journal-title":"Br J Haematol"},{"issue":"1","key":"5733_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"3","key":"5733_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bjh.12152","volume":"160","author":"R Rosovsky","year":"2013","unstructured":"Rosovsky R et al (2013) Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol 160(3):351\u2013358","journal-title":"Br J Haematol"},{"issue":"3","key":"5733_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clml.2020.11.015","volume":"21","author":"JN Patel","year":"2021","unstructured":"Patel JN et al (2021) Thromboembolism incidence and risk factors in multiple myeloma after first exposure to Immunomodulatory Drug-based regimens. Clin Lymphoma Myeloma Leuk 21(3):188\u2013198e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5733_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK et al (2020) Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(10):1317\u20131330","journal-title":"Lancet Oncol"},{"issue":"1","key":"5733_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.17772","volume":"196","author":"K Piedra","year":"2022","unstructured":"Piedra K et al (2022) Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol 196(1):105\u2013109","journal-title":"Br J Haematol"},{"issue":"4","key":"5733_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M et al (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9(4):653\u2013663","journal-title":"J Thromb Haemost"},{"issue":"10","key":"5733_CR37","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266","journal-title":"Haematologica"},{"issue":"6","key":"5733_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A et al (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587\u2013600","journal-title":"J Clin Oncol"},{"issue":"9513","key":"5733_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825\u2013831","journal-title":"Lancet"},{"issue":"1","key":"5733_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16\u201319","journal-title":"J Clin Oncol"},{"issue":"13","key":"5733_CR41","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106(13):4050\u20134053","journal-title":"Blood"},{"issue":"11","key":"5733_CR42","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94(11):1176\u20131184","journal-title":"Am J Hematol"},{"issue":"7","key":"5733_CR43","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A et al (2019) Derivation and validation of a risk Assessment Model for Immunomodulatory Drug-Associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 17(7):840\u2013847","journal-title":"J Natl Compr Canc Netw"},{"issue":"Supplement 1","key":"5733_CR44","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1182\/blood-2023-182926","volume":"142","author":"A Sekar","year":"2023","unstructured":"Sekar A et al (2023) External validation of PRISM score in multiple myeloma patients in a community setting: a retrospective cohort study. Blood 142(Supplement 1):4721\u20134721","journal-title":"Blood"},{"issue":"2","key":"5733_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bjh.18630","volume":"201","author":"D Dima","year":"2023","unstructured":"Dima D et al (2023) External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol 201(2):280\u2013284","journal-title":"Br J Haematol"},{"issue":"10","key":"5733_CR46","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM et al (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10(10):e825\u2013e837","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"5733_CR47","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1182\/blood-2023-190746","volume":"142","author":"S Rosqvist","year":"2023","unstructured":"Rosqvist S et al (2023) High rates of thrombotic events in newly diagnosed multiple myeloma patients enrolled on the Maia Trial. Blood 142(Supplement 1):4718\u20134718","journal-title":"Blood"},{"key":"5733_CR48","doi-asserted-by":"publisher","first-page":"107602962311776","DOI":"10.1177\/10760296231177678","volume":"29","author":"H Awada","year":"2023","unstructured":"Awada H et al (2023) Risk of venous thromboembolism in multiple myeloma patients during the Immediate Peri-autologous hematopoietic cell transplantation phase. Clin Appl Thromb Hemost 29:10760296231177678","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"5733_CR49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/j.seminhematol.2017.08.002","volume":"55","author":"G Zoppellaro","year":"2018","unstructured":"Zoppellaro G et al (2018) Primary thromboembolic prevention in multiple myeloma patients: an exploratory meta-analysis on aspirin use. Semin Hematol 55(4):182\u2013184","journal-title":"Semin Hematol"},{"key":"5733_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","volume":"141","author":"F Al-Ani","year":"2016","unstructured":"Al-Ani F et al (2016) Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res 141:84\u201390","journal-title":"Thromb Res"},{"issue":"8","key":"5733_CR51","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/jth.15758","volume":"20","author":"E Chalayer","year":"2022","unstructured":"Chalayer E et al (2022) Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM\/DFCI 2009 cohort. J Thromb Haemost 20(8):1859\u20131867","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5733_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS et al (2022) NCCN Guidelines\u00ae insights: multiple myeloma, Version 3.2022. J Natl Compr Canc Netw 20(1):8\u201319","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"5733_CR53","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA et al (2019) Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory patients with Cancer. N Engl J Med 380(8):720\u2013728","journal-title":"N Engl J Med"},{"issue":"8","key":"5733_CR54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M et al (2019) Apixaban to prevent venous thromboembolism in patients with Cancer. N Engl J Med 380(8):711\u2013719","journal-title":"N Engl J Med"},{"issue":"4","key":"5733_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjh.16653","volume":"190","author":"RF Cornell","year":"2020","unstructured":"Cornell RF et al (2020) Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 190(4):555\u2013561","journal-title":"Br J Haematol"},{"issue":"6","key":"5733_CR56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ajh.25459","volume":"94","author":"B Pegourie","year":"2019","unstructured":"Pegourie B et al (2019) Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 94(6):635\u2013640","journal-title":"Am J Hematol"},{"issue":"1","key":"5733_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjh.15392","volume":"185","author":"NPF Storrar","year":"2019","unstructured":"Storrar NPF et al (2019) Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol 185(1):142\u2013144","journal-title":"Br J Haematol"},{"key":"5733_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fonc.2019.00045","volume":"9","author":"RF Cornell","year":"2019","unstructured":"Cornell RF et al (2019) Apixaban for Primary Prevention of venous thromboembolism in patients with multiple myeloma receiving Immunomodulatory Therapy. Front Oncol 9:45","journal-title":"Front Oncol"},{"issue":"3","key":"5733_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11239-017-1534-9","volume":"44","author":"L Man","year":"2017","unstructured":"Man L et al (2017) Use of direct oral anticoagulants in patients on immunomodulatory agents. J Thromb Thrombolysis 44(3):298\u2013302","journal-title":"J Thromb Thrombolysis"},{"issue":"19","key":"5733_CR60","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782\u20131791","journal-title":"N Engl J Med"},{"issue":"19","key":"5733_CR61","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770\u20131781","journal-title":"N Engl J Med"},{"issue":"12","key":"5733_CR62","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F et al (2021) Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 22(12):1705\u20131720","journal-title":"Lancet Oncol"},{"issue":"1","key":"5733_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338","journal-title":"Lancet Oncol"},{"issue":"2","key":"5733_CR64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152","journal-title":"N Engl J Med"},{"issue":"12","key":"5733_CR65","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG et al (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123(12):1826\u20131832","journal-title":"Blood"},{"issue":"14","key":"5733_CR66","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA et al (2016) Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331","journal-title":"N Engl J Med"},{"issue":"6","key":"5733_CR67","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA et al (2021) Daratumumab plus Pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 22(6):801\u2013812","journal-title":"Lancet Oncol"},{"issue":"5","key":"5733_CR68","first-page":"807","volume":"99","author":"E Gray","year":"2008","unstructured":"Gray E, Mulloy B, Barrowcliffe TW (2008) Heparin and low-molecular-weight heparin. Thromb Haemost 99(5):807\u2013818","journal-title":"Thromb Haemost"},{"issue":"1","key":"5733_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M22-1258","volume":"176","author":"S Gulati","year":"2023","unstructured":"Gulati S, Eckman MH (2023) Anticoagulant therapy for Cancer-Associated thrombosis: a cost-effectiveness analysis. Ann Intern Med 176(1):1\u20139","journal-title":"Ann Intern Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05733-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05733-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05733-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:03:09Z","timestamp":1729933389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05733-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5733"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05733-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"24 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}